Microscopic colitis is a chronic inflammatory condition, and for most people it is managed rather than cured outright. That said, the picture is more encouraging than the word “chronic” might suggest. Roughly a third or more of patients experience spontaneous remission without prescription treatment, and the first-line medication, budesonide, drives symptoms into remission in most of those who need it. The catch is that stopping treatment often brings the diarrhea back, which is why gastroenterologists tend to frame microscopic colitis as a condition you control over time rather than one you eliminate with a single course of therapy.
What Microscopic Colitis Actually Does
Microscopic colitis gets its name from the fact that the colon looks normal during a standard colonoscopy. The inflammation only shows up under a microscope, in biopsies taken from colon tissue that appears perfectly healthy to the naked eye. Current understanding points to a combination of immune system overreaction, shifts in gut bacteria, and a breakdown in the gut’s protective lining as the drivers of the condition.1PubMed Central. Microscopic colitis-microbiome, barrier function and associated diseases The hallmark symptom is persistent, watery, non-bloody diarrhea, often accompanied by urgency, nighttime episodes, and abdominal cramping.2PubMed Central. Microscopic colitis in older adults: impact, diagnosis, and management
There are two main subtypes, collagenous colitis and lymphocytic colitis, distinguished by the type of microscopic changes in the colon wall. From a patient’s perspective, the symptoms and treatment are largely the same for both.3PubMed Central. Management of microscopic colitis: challenges and solutions One interesting wrinkle is that the subtypes are not always fixed. Somewhere between 2% and 14% of patients convert from one form to the other over time, with lymphocytic colitis shifting to collagenous colitis more often than the reverse.4Elsevier ScienceDirect (Human Pathology). Review Microscopic colitis: lymphocytic colitis, collagenous colitis, and beyond
Spontaneous Remission Happens More Often Than You Might Think
One of the more hopeful aspects of microscopic colitis is that a meaningful portion of people get better on their own. In an Irish study, about 38% of patients achieved spontaneous remission with either no treatment at all or just over-the-counter anti-diarrheal medications like loperamide. Male gender was the only factor independently associated with a higher chance of spontaneous resolution.5PubMed. Microscopic colitis: clinical characteristics, treatment and outcomes in an Irish population So for a subset of patients, “cure” in the practical sense does happen: the diarrhea stops, the inflammation quiets down, and it stays that way without ongoing medication.
The problem is that there is no reliable way to predict ahead of time who will fall into this lucky group. A gastroenterologist might suggest a trial of simple anti-diarrheals first, especially if symptoms are mild, but many patients will eventually need something stronger.
Why Budesonide Works So Well but Does Not Cure
Budesonide, a locally acting steroid that targets the gut with relatively few body-wide side effects, is the go-to treatment. It is effective for inducing remission in both collagenous colitis and lymphocytic colitis.6PubMed Central. Use of budesonide in the treatment of microscopic colitis One randomized trial even found benefits in patients with “incomplete” microscopic colitis, where budesonide significantly reduced the number of watery stools and improved quality of life compared to placebo.7PubMed Central. Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo-controlled multicentre trial
The frustration is what happens after you stop taking it. A systematic review and meta-analysis found that after stopping induction therapy, roughly half of patients relapsed. After stopping a maintenance course, the recurrence rate was similar, around 58%. Taking both categories together, the overall recurrence rate after any course of budesonide was about 53%.8Inflammatory Bowel Diseases. Effectiveness and Safety Profile of Budesonide Maintenance in Microscopic Colitis: A Systematic Review and Meta-Analysis A randomized 12-month trial of low-dose budesonide for collagenous colitis painted a similar picture: about 61% of patients on budesonide maintained remission at one year, compared to just 17% on placebo. But when those successfully treated patients stopped the drug, over 80% relapsed.9Gut. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial
This is the core reason microscopic colitis is described as managed rather than cured. Budesonide controls inflammation effectively while you take it, and many patients do well on a low maintenance dose of around 3 to 6 mg per day for months or years. The same meta-analysis found that the overall remission rate on maintenance budesonide was about 84%.8Inflammatory Bowel Diseases. Effectiveness and Safety Profile of Budesonide Maintenance in Microscopic Colitis: A Systematic Review and Meta-Analysis But taking a steroid indefinitely, even a locally acting one, is not the same as being cured.
When Medications Are the Cause
One scenario where something closer to a genuine cure is possible involves drug-triggered microscopic colitis. Several common medications are associated with a significantly higher risk of developing the condition. A systematic review and meta-analysis found that proton pump inhibitors (the heartburn drugs like omeprazole) roughly tripled the odds, with an adjusted odds ratio of 2.65. SSRIs (antidepressants like sertraline and fluoxetine) roughly doubled them. NSAIDs (ibuprofen, naproxen, and similar painkillers) and statins (cholesterol-lowering drugs) also carried elevated risk.10PubMed Central. Are Drugs Associated with Microscopic Colitis? A Systematic Review and Meta-Analysis
If a medication is the primary trigger, stopping it, or switching to an alternative, can sometimes resolve symptoms entirely. This is one of the first things a gastroenterologist should evaluate. Of course, many patients take these medications for important reasons and can’t simply quit them, and not every case of microscopic colitis in someone taking a PPI or NSAID is caused by that drug. Still, the drug-trigger pathway is the clearest route to something that looks like a cure for a meaningful minority of patients.
What Happens When Budesonide Is Not Enough
Somewhere between 1% and 6% of patients with microscopic colitis are considered refractory, meaning budesonide either doesn’t work for them, causes intolerable side effects, or can’t be tapered without constant relapse.11PubMed Central. Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis For these patients, the options become more limited and the evidence thinner.
Biologic drugs, the same class of medications used for Crohn’s disease and ulcerative colitis, have been tried. A multicenter study of 14 patients with budesonide-refractory or budesonide-dependent disease found that about 36% achieved steroid-free remission at 12 weeks on anti-TNF therapy (all of whom received infliximab). By one year, accounting for patients who switched between different anti-TNF agents, half were in clinical remission.12PubMed. Biologic Therapy for Budesonide-refractory, -dependent or -intolerant Microscopic Colitis: a Multicentre Cohort Study from the GETAID Results with vedolizumab and ustekinumab were much less encouraging in the same study, with only one of three patients responding.13Journal of Crohn’s and Colitis. Biologic Therapy for Budesonide-refractory, -dependent or -intolerant Microscopic Colitis: a Multicentre Cohort Study from the GETAID These numbers come from very small studies, so drawing firm conclusions is difficult, but they offer at least some hope for the hardest-to-treat cases.
In the most extreme and rare scenarios, surgical diversion of the bowel (an ileostomy) has been reported as an option, though it is essentially a last resort when all medical therapy has failed.14PubMed Central. Microscopic colitis: A review of etiology, treatment and refractory disease Fecal microbiota transplantation has been explored in case reports for refractory collagenous colitis, but this remains experimental and far from standard practice.11PubMed Central. Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis
The Diagnostic Problem That Delays Treatment
Part of what makes microscopic colitis harder to manage is that it often takes a long time to get diagnosed in the first place. Because the colon looks normal on colonoscopy and the main symptom is chronic watery diarrhea, many patients are initially told they have irritable bowel syndrome with diarrhea (IBS-D). In one study of 247 patients thought to have IBS-D, about 6% actually had microscopic colitis when biopsies were finally taken from normal-appearing mucosa.15PubMed Central. Microscopic colitis – a missed diagnosis in diarrhea-predominant irritable bowel syndrome This matters because an IBS diagnosis means you typically get dietary advice and maybe antispasmodics, neither of which addresses the underlying inflammation. The correct diagnosis requires multiple biopsies from different sections of the colon, even when everything looks normal, and not every colonoscopy routinely includes these.
If you have been living with chronic watery diarrhea and have been told it is just IBS, it is worth asking whether biopsies were taken. The treatment for microscopic colitis is different and typically more effective than IBS management.
Smoking, Lifestyle, and Risk
Smoking is one of the strongest modifiable risk factors. A large prospective cohort study of U.S. women found that current smokers had roughly two and a half times the risk of developing microscopic colitis compared to non-smokers, and past smokers still carried about one and a half times the risk. Risk increased with more pack-years of smoking and decreased with time since quitting.16Oxford University Press. Smoking is Associated with an Increased Risk of Microscopic Colitis: Results From Two Large Prospective Cohort Studies of US Women Quitting smoking will not cure existing microscopic colitis, but it removes a significant driver and may reduce the intensity or frequency of flares.
Microscopic colitis is more common in older adults and in women, with incidence rates climbing steeply after age 50. Collagenous colitis in particular skews heavily female.17PubMed Central. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota Other identified risk factors include alcohol use, prior gastrointestinal infections, and existing immune-mediated diseases.18PubMed Central. Update on the Epidemiology and Management of Microscopic Colitis
Bile Acid Malabsorption and Overlapping Conditions
A surprisingly common companion to microscopic colitis is bile acid malabsorption, where the body fails to properly reabsorb bile acids in the small intestine, leading to more watery diarrhea. In one study, about 43% of patients with microscopic colitis also had bile acid malabsorption, and the overlap was even higher in the lymphocytic colitis subtype, at 60%.19PubMed. Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea This is clinically relevant because bile acid malabsorption can be treated with bile acid sequestrants (like cholestyramine), and addressing it can substantially reduce diarrhea even if the microscopic colitis itself is not fully controlled. If you are being treated for microscopic colitis and your diarrhea is not improving as expected, bile acid malabsorption is worth investigating.
The Autoimmune Connection
Microscopic colitis does not exist in a vacuum. It clusters with autoimmune diseases at a rate that goes well beyond coincidence. A large Danish case-control study found that about 22% of patients with microscopic colitis had at least one concomitant autoimmune disease, compared to 11% of matched controls. The association was particularly strong with gastrointestinal and endocrine autoimmune conditions, as well as connective tissue disorders.20PubMed. Autoimmune diseases in microscopic colitis: A Danish nationwide case-control study
Celiac disease stands out. A systematic review and meta-analysis found that celiac disease was present in about 6% of patients with microscopic colitis, and microscopic colitis was present in about 6% of patients with celiac disease, representing a more than eightfold increased odds of association.21PubMed Central. The association between microscopic colitis and celiac disease: a systematic review and meta-analysis This overlap has practical implications: if you have microscopic colitis and have never been tested for celiac disease, screening is reasonable, especially if a strict gluten-free diet seems to help your symptoms. And if you have celiac disease but your diarrhea persists despite strict gluten avoidance, microscopic colitis could be the missing piece.
Autoimmune thyroid diseases, including Hashimoto’s thyroiditis and Graves’ disease, are also more common in microscopic colitis patients. A large Swedish study found that about 12% of patients with microscopic colitis had autoimmune thyroid disease, compared to about 8% of matched controls. The association was strongest in patients diagnosed with microscopic colitis before age 50.22The Journal of Clinical Endocrinology & Metabolism. Autoimmune Thyroid Diseases and Microscopic Colitis: A Nationwide Matched Case–Control Study in Sweden
The Good News About Cancer Risk
One worry that many patients have, understandably, is whether chronic colon inflammation means a higher risk of colon cancer. Unlike ulcerative colitis and Crohn’s disease, where long-standing inflammation does increase cancer risk, microscopic colitis does not appear to carry this burden. A retrospective cohort study found that patients with microscopic colitis had similar odds of developing colon polyps and cancer as colonoscopy controls, and even patients with multiple episodes of microscopic colitis showed no elevated risk.23PubMed Central. Cancer risk in microscopic colitis: a retrospective cohort study A separate systematic review found no association with malignancy across most studies, with some even suggesting a reduced risk compared to controls, though the authors cautioned that follow-up periods were relatively short.24PubMed. Microscopic colitis and its associations with complications observed in classic inflammatory bowel disease: a systematic review This is genuinely reassuring and distinguishes microscopic colitis sharply from its more aggressive inflammatory bowel disease relatives.
The Emotional Weight of an Invisible Disease
Something that often gets lost in clinical discussions is how profoundly microscopic colitis affects daily life, particularly because the disease is invisible to others. Qualitative research has documented that patients struggle not just with the frequency and urgency of diarrhea, but with the constant anxiety of being far from a bathroom. Fecal incontinence, embarrassment, and the feeling of being unable to explain the condition to friends and family compound the physical symptoms.25PubMed Central. Microscopic colitis: Struggling with an invisible, disabling disease Studies have consistently found that all measured dimensions of quality of life, from symptom burden to social functioning to disease-related worry, are impaired during active disease.26PubMed. Long-term prognosis of clinical symptoms and health-related quality of life in microscopic colitis: a case-control study
The experience does not always correlate with how “bad” the disease looks on paper. Someone with four watery stools a day can be more debilitated than someone with eight, depending on urgency, timing, and the individual’s access to bathrooms throughout the day. This mismatch between objective measures and lived experience is something worth being aware of, both for patients trying to communicate with their doctors and for doctors deciding how aggressively to treat.
What Gut Bacteria Research Might Eventually Change
The gut microbiome is increasingly recognized as part of the microscopic colitis puzzle, and research in this area could eventually shift the disease from “managed” to something more durably treatable. Systematic reviews have identified consistent patterns in the bacterial communities of people with microscopic colitis. One of the most reproducible findings is a decrease in Akkermansia muciniphila, a bacterium known for maintaining the mucus layer of the gut, across multiple studies using fecal samples.27PubMed Central. Microbiome Composition in Microscopic Colitis: A Systematic Review More recent research has confirmed reduced microbial diversity overall, along with an enrichment of inflammation-associated bacteria that normally live in the mouth, like Veillonella dispar, and a loss of protective species.28PubMed Central. Dysbiosis of Gut Microbiota in Microscopic Colitis: Diagnostic and Therapeutic Implications
Whether restoring a healthier microbial balance could produce lasting remission is an open question. Fecal microbiota transplantation has been attempted in individual case reports for refractory collagenous colitis, but there are no controlled trials yet to draw conclusions from. The microbiome findings are more useful at this stage for understanding why microscopic colitis happens than for treating it, though that balance could shift as targeted probiotic and microbial therapies develop.
Living with Microscopic Colitis Long-Term
For most people, microscopic colitis settles into a pattern over time. Some have a single episode that resolves spontaneously and never returns. Some need a course of budesonide, taper off successfully, and stay in remission. And some need low-dose maintenance therapy for years, with occasional adjustments. The disease does not progress to more severe forms of inflammatory bowel disease, it does not appear to increase cancer risk, and it does not shorten life expectancy. What it does do is demand attention: awareness of potential drug triggers, communication with your gastroenterologist about bile acid malabsorption and coexisting autoimmune conditions, and honest reporting of how symptoms affect your ability to function day to day. If you have been managing microscopic colitis for years without a medication review, it is worth revisiting whether any of the drugs in your medicine cabinet could be contributing to ongoing flares, and whether treatments you were offered early in the diagnosis are still the best fit for where the disease stands now.